

Michael N Pollak

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8639656/publications.pdf>

Version: 2024-02-01

491
papers

48,954
citations

1893

102
h-index

2076

204
g-index

498
all docs

498
docs citations

498
times ranked

45906
citing authors

#	ARTICLE	IF	CITATIONS
1	Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study. <i>Science</i> , 1998, 279, 563-566.	12.6	1,872
2	Insulin and insulin-like growth factor signalling in neoplasia. <i>Nature Reviews Cancer</i> , 2008, 8, 915-928.	28.4	1,792
3	Circulating concentrations of insulin-like growth factor I and risk of breast cancer. <i>Lancet</i> , The, 1998, 351, 1393-1396.	13.7	1,706
4	Diabetes and Cancer. <i>Diabetes Care</i> , 2010, 33, 1674-1685.	8.6	1,618
5	Insulin-like growth factors and neoplasia. <i>Nature Reviews Cancer</i> , 2004, 4, 505-518.	28.4	1,422
6	Metformin improves healthspan and lifespan in mice. <i>Nature Communications</i> , 2013, 4, 2192.	12.8	1,118
7	Prospective Study of Colorectal Cancer Risk in Men and Plasma Levels of Insulin-Like Growth Factor (IGF)-I and IGF-Binding Protein-3. <i>Journal of the National Cancer Institute</i> , 1999, 91, 620-625.	6.3	1,022
8	Metformin: From Mechanisms of Action to Therapies. <i>Cell Metabolism</i> , 2014, 20, 953-966.	16.2	1,019
9	Anastrozole Is Superior to Tamoxifen as First-Line Therapy for Advanced Breast Cancer in Postmenopausal Women: Results of a North American Multicenter Randomized Trial. <i>Journal of Clinical Oncology</i> , 2000, 18, 3758-3767.	1.6	973
10	Metformin Is an AMP Kinase-Dependent Growth Inhibitor for Breast Cancer Cells. <i>Cancer Research</i> , 2006, 66, 10269-10273.	0.9	972
11	The insulin and insulin-like growth factor receptor family in neoplasia: an update. <i>Nature Reviews Cancer</i> , 2012, 12, 159-169.	28.4	929
12	Metformin Inhibits Mammalian Target of Rapamycin-Dependent Translation Initiation in Breast Cancer Cells. <i>Cancer Research</i> , 2007, 67, 10804-10812.	0.9	845
13	Insulin-Like Growth Factor-I Receptor Signaling and Resistance to Trastuzumab (Herceptin). <i>Journal of the National Cancer Institute</i> , 2001, 93, 1852-1857.	6.3	815
14	Diabetes and Cancer: A Consensus Report. <i>Ca-A Cancer Journal for Clinicians</i> , 2010, 60, 207-221.	329.8	724
15	mTORC1 Controls Mitochondrial Activity and Biogenesis through 4E-BP-Dependent Translational Regulation. <i>Cell Metabolism</i> , 2013, 18, 698-711.	16.2	647
16	Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development. <i>Nature Medicine</i> , 2014, 20, 1193-1198.	30.7	510
17	Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria. <i>Biochemical Journal</i> , 2014, 462, 475-487.	3.7	502
18	eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 14134-14139.	7.1	447

#	ARTICLE	IF	CITATIONS
19	Investigating Metformin for Cancer Prevention and Treatment: The End of the Beginning. <i>Cancer Discovery</i> , 2012, 2, 778-790.	9.4	443
20	Metformin inhibits the senescence-associated secretory phenotype by interfering with IKK/NF- κ B activation. <i>Aging Cell</i> , 2013, 12, 489-498.	6.7	422
21	mTOR coordinates protein synthesis, mitochondrial activity and proliferation. <i>Cell Cycle</i> , 2015, 14, 473-480.	2.6	397
22	The Type 1 Insulin-Like Growth Factor Receptor Pathway. <i>Clinical Cancer Research</i> , 2008, 14, 6364-6370.	7.0	387
23	Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. <i>Lancet Oncology</i> , The, 2008, 9, 1039-1047.	10.7	385
24	Insulin-Like Growth Factor-I (IGF-I) and IGF Binding Protein-3 as Predictors of Advanced-Stage Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2002, 94, 1099-1106.	6.3	377
25	Phosphorylated Insulin-Like Growth Factor-I/Insulin Receptor Is Present in All Breast Cancer Subtypes and Is Related to Poor Survival. <i>Cancer Research</i> , 2008, 68, 10238-10246.	0.9	364
26	The eEF2 Kinase Confers Resistance to Nutrient Deprivation by Blocking Translation Elongation. <i>Cell</i> , 2013, 153, 1064-1079.	28.9	348
27	Metformin directly acts on mitochondria to alter cellular bioenergetics. <i>Cancer & Metabolism</i> , 2014, 2, 12.	5.0	330
28	Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial. <i>Lancet Oncology</i> , The, 2015, 16, 839-847.	10.7	321
29	A Prospective Study of Plasma C-Peptide and Colorectal Cancer Risk in Men. <i>Journal of the National Cancer Institute</i> , 2004, 96, 546-553.	6.3	311
30	MDA-468, a human breast cancer cell line with a high number of epidermal growth factor (EGF) receptors, has an amplified EGF receptor gene and is growth inhibited by EGF. <i>Biochemical and Biophysical Research Communications</i> , 1985, 128, 898-905.	2.1	300
31	Obesity, Diabetes, and Risk of Prostate Cancer: Results from the Prostate Cancer Prevention Trial. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 1977-1983.	2.5	300
32	Metformin Reduces Endogenous Reactive Oxygen Species and Associated DNA Damage. <i>Cancer Prevention Research</i> , 2012, 5, 536-543.	1.5	284
33	Insulin-like growth factor physiology and cancer risk. <i>European Journal of Cancer</i> , 2000, 36, 1224-1228.	2.8	267
34	The Effects of Adiponectin and Metformin on Prostate and Colon Neoplasia Involve Activation of AMP-Activated Protein Kinase. <i>Cancer Prevention Research</i> , 2008, 1, 369-375.	1.5	266
35	Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. <i>Oncogene</i> , 2009, 28, 3009-3021.	5.9	265
36	Insulin-like Growth Factors, Their Binding Proteins, and Prostate Cancer Risk: Analysis of Individual Patient Data from 12 Prospective Studies. <i>Annals of Internal Medicine</i> , 2008, 149, 461.	3.9	263

#	ARTICLE	IF	CITATIONS
37	Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells. <i>Oncogene</i> , 2005, 24, 4281-4292.	5.9	251
38	In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2008, 110, 246-250.	1.4	249
39	mTOR as a central regulator of lifespan and aging. <i>F1000Research</i> , 2019, 8, 998.	1.6	244
40	The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. <i>BMJ, The</i> , 2012, 344, e3645-e3645.	6.0	237
41	A Prospective Evaluation of Insulin and Insulin-like Growth Factor-I as Risk Factors for Endometrial Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 921-929.	2.5	224
42	A framework for selection of blood-based biomarkers for geroscience-guided clinical trials: report from the TAME Biomarkers Workgroup. <i>GeroScience</i> , 2018, 40, 419-436.	4.6	221
43	Genetic polymorphisms of the vitamin D binding protein and plasma concentrations of 25-hydroxyvitamin D in premenopausal women. <i>American Journal of Clinical Nutrition</i> , 2009, 89, 634-640.	4.7	214
44	Insulin, the Insulin-Like Growth Factor Axis, and Mortality in Patients With Nonmetastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 176-185.	1.6	208
45	A Prospective Study of C-Peptide, Insulin-like Growth Factor-I, Insulin-like Growth Factor Binding Protein-1, and the Risk of Colorectal Cancer in Women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 850-855.	2.5	206
46	Metformin and Other Biguanides in Oncology: Advancing the Research Agenda. <i>Cancer Prevention Research</i> , 2010, 3, 1060-1065.	1.5	205
47	Insulin receptor expression by human prostate cancers. <i>Prostate</i> , 2009, 69, 33-40.	2.3	203
48	Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase. <i>Endocrine-Related Cancer</i> , 2010, 17, 351-360.	3.1	203
49	Randomized Phase II Study of Two Doses of Gefitinib in Hormone-Refractory Prostate Cancer: A Trial of the National Cancer Institute of Canada-Clinical Trials Group. <i>Journal of Clinical Oncology</i> , 2005, 23, 455-460.	1.6	195
50	Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells. <i>International Journal of Cancer</i> , 2004, 108, 334-341.	5.1	193
51	Estradiol and Antiestrogens Regulate a Growth Inhibitory Insulin-like Growth Factor Binding Protein 3 Autocrine Loop in Human Breast Cancer Cells. <i>Journal of Biological Chemistry</i> , 1996, 271, 1016-1021.	3.4	190
52	A Neanderthal OAS1 isoform protects individuals of European ancestry against COVID-19 susceptibility and severity. <i>Nature Medicine</i> , 2021, 27, 659-667.	30.7	188
53	Potential Applications for Circulating Tumor Cells Expressing the Insulin-Like Growth Factor-I Receptor. <i>Clinical Cancer Research</i> , 2007, 13, 3611-3616.	7.0	185
54	Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells. <i>Breast Cancer Research and Treatment</i> , 2010, 123, 271-279.	2.5	179

#	ARTICLE	IF	CITATIONS
55	Novel Promoter Polymorphism in Insulin-Like Growth Factor-Binding Protein-3: Correlation with Serum Levels and Interaction with Known Regulators ¹ . <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 1274-1280.	3.6	178
56	Metformin Decreases Glucose Oxidation and Increases the Dependency of Prostate Cancer Cells on Reductive Glutamine Metabolism. <i>Cancer Research</i> , 2013, 73, 4429-4438.	0.9	178
57	nanoCAGE reveals 5' UTR features that define specific modes of translation of functionally related MTOR-sensitive mRNAs. <i>Genome Research</i> , 2016, 26, 636-648.	5.5	177
58	Distinct perturbation of the translome by the antidiabetic drug metformin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 8977-8982.	7.1	169
59	Milk Intake, Circulating Levels of Insulin-Like Growth Factor-I, and Risk of Colorectal Cancer in Men. <i>Journal of the National Cancer Institute</i> , 2001, 93, 1330-1336.	6.3	168
60	Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth. <i>Endocrine-Related Cancer</i> , 2008, 15, 833-839.	3.1	165
61	Systemic cancer therapy: achievements and challenges that lie ahead. <i>Frontiers in Pharmacology</i> , 2013, 4, 57.	3.5	165
62	Circulating Levels of Insulin-like Growth Factors, their Binding Proteins, and Breast Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 699-704.	2.5	164
63	Cancer, obesity, diabetes, and antidiabetic drugs: is the fog clearing?. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 85-99.	27.6	163
64	Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women. <i>Cancer</i> , 1997, 80, 435-441.	4.1	162
65	Effects of Lycopene Supplementation in Patients with Localized Prostate Cancer. <i>Experimental Biology and Medicine</i> , 2002, 227, 881-885.	2.4	162
66	Potential applications for biguanides in oncology. <i>Journal of Clinical Investigation</i> , 2013, 123, 3693-3700.	8.2	162
67	Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo. <i>Oncogene</i> , 2011, 30, 1174-1182.	5.9	161
68	Association of Diet-Induced Hyperinsulinemia With Accelerated Growth of Prostate Cancer (LNCaP) Xenografts. <i>Journal of the National Cancer Institute</i> , 2007, 99, 1793-1800.	6.3	160
69	Mammary-specific deletion of parathyroid hormone-related protein preserves bone mass during lactation. <i>Journal of Clinical Investigation</i> , 2003, 112, 1429-1436.	8.2	156
70	Systemic Correlates of White Adipose Tissue Inflammation in Early-Stage Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 2283-2289.	7.0	154
71	Novel Promoter Polymorphism in Insulin-Like Growth Factor-Binding Protein-3: Correlation with Serum Levels and Interaction with Known Regulators. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 1274-1280.	3.6	154
72	High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by Notch signaling. <i>Journal of Experimental Medicine</i> , 2011, 208, 1809-1822.	8.5	153

#	ARTICLE	IF	CITATIONS
73	Phase I, Pharmacokinetic and Pharmacodynamic Study of the Anti-Insulinlike Growth Factor Type 1 Receptor Monoclonal Antibody CP-751,871 in Patients With Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2008, 26, 3196-3203.	1.6	152
74	Soy Isoflavones in the Treatment of Prostate Cancer. <i>Nutrition and Cancer</i> , 2003, 47, 111-117.	2.0	150
75	Hyperglycemia, Insulin Resistance, Impaired Pancreatic β -Cell Function, and Risk of Pancreatic Cancer. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1027-1035.	6.3	146
76	Insulin-like Growth Factor Binding Protein-3 Induces Apoptosis in MCF7 Breast Cancer Cells. <i>Biochemical and Biophysical Research Communications</i> , 1997, 237, 690-693.	2.1	145
77	Insulin-like growth factors and prostate cancer. <i>Cancer and Metastasis Reviews</i> , 1998, 17, 383-390.	5.9	142
78	A study of high-dose oral silybin phytosome followed by prostatectomy in patients with localized prostate cancer. <i>Prostate</i> , 2010, 70, 848-855.	2.3	141
79	Are Metformin Doses Used in Murine Cancer Models Clinically Relevant?. <i>Cell Metabolism</i> , 2016, 23, 569-570.	16.2	140
80	Mechanisms of Antineoplastic Action of Somatostatin Analogs. <i>Experimental Biology and Medicine</i> , 1998, 217, 143-152.	2.4	134
81	Insulin-Like Growth Factor-I, IGF-Binding Protein-3, and Mammographic Breast Density. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 1065-1073.	2.5	134
82	Presence of somatomedin receptors on primary human breast and colon carcinomas. <i>Cancer Letters</i> , 1987, 38, 223-230.	7.2	131
83	Circulating IGF-I: New Perspectives for a New Century. <i>Trends in Endocrinology and Metabolism</i> , 1999, 10, 136-141.	7.1	128
84	Diabetes mellitus and cancer risk in a population-based case-control study among men from Montreal, Canada. <i>International Journal of Cancer</i> , 2006, 118, 2105-2109.	5.1	126
85	Dietary correlates of plasma insulin-like growth factor I and insulin-like growth factor binding protein 3 concentrations. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2002, 11, 852-61.	2.5	126
86	IGFBP7 Binds to the IGF-1 Receptor and Blocks Its Activation by Insulin-Like Growth Factors. <i>Science Signaling</i> , 2012, 5, ra92.	3.6	123
87	Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II. <i>Endocrine-Related Cancer</i> , 2006, 13, 583-592.	3.1	120
88	Metformin and the Incidence of Prostate Cancer in Patients with Type 2 Diabetes. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 337-344.	2.5	120
89	Randomized Phase II Trial of Custirsen (OGX-011) in Combination with Docetaxel or Mitoxantrone as Second-line Therapy in Patients with Metastatic Castrate-Resistant Prostate Cancer Progressing after First-line Docetaxel: CUOG Trial P-06c. <i>Clinical Cancer Research</i> , 2011, 17, 5765-5773.	7.0	120
90	Reproducibility of Plasma Steroid Hormones, Prolactin, and Insulin-like Growth Factor Levels among Premenopausal Women over a 2- to 3-Year Period. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 972-978.	2.5	118

#	ARTICLE	IF	CITATIONS
91	Insulin-like growth factor receptor (IGF-1R) in breast cancer subtypes. <i>Breast Cancer Research and Treatment</i> , 2012, 132, 131-142.	2.5	117
92	A Meta-analysis of Individual Participant Data Reveals an Association between Circulating Levels of IGF-I and Prostate Cancer Risk. <i>Cancer Research</i> , 2016, 76, 2288-2300.	0.9	117
93	Insulin-Like Growth Factor Axis and Risk of Type 2 Diabetes in Women. <i>Diabetes</i> , 2012, 61, 2248-2254.	0.6	116
94	Reduced mammary gland carcinogenesis in transgenic mice expressing a growth hormone antagonist. <i>British Journal of Cancer</i> , 2001, 85, 428-430.	6.4	114
95	Metabolic Obesity, Adipose Inflammation and Elevated Breast Aromatase in Women with Normal Body Mass Index. <i>Cancer Prevention Research</i> , 2017, 10, 235-243.	1.5	114
96	Induction of apoptosis by metformin in epithelial ovarian cancer: Involvement of the Bcl-2 family proteins. <i>Gynecologic Oncology</i> , 2011, 121, 492-498.	1.4	113
97	Serine Deprivation Enhances Antineoplastic Activity of Biguanides. <i>Cancer Research</i> , 2014, 74, 7521-7533.	0.9	113
98	Metformin regulates metabolic and nonmetabolic pathways in skeletal muscle and subcutaneous adipose tissues of older adults. <i>Aging Cell</i> , 2018, 17, e12723.	6.7	113
99	Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells. <i>Breast Cancer Research</i> , 2005, 7, R570-9.	5.0	112
100	Nutritional predictors of insulin-like growth factor I and their relationships to cancer in men. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2003, 12, 84-9.	2.5	112
101	Castration-Induced Apoptosis in the Rat Ventral Prostate Is Associated with Increased Expression of Genes Encoding Insulin-Like Growth Factor Binding Proteins 2, 3, 4 and 5. <i>Endocrinology</i> , 1998, 139, 807-810.	2.8	110
102	Association of Total Insulin-Like Growth Factor-I, Insulin-Like Growth Factor Binding Protein-1 (IGFBP-1), and IGFBP-3 Levels with Incident Coronary Events and Ischemic Stroke. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 1319-1325.	3.6	110
103	Assessment of the prognostic and predictive utility of the Breast Cancer Index (BCI): an NCIC CTG MA.14 study. <i>Breast Cancer Research</i> , 2016, 18, 1.	5.0	110
104	Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes. <i>Breast Cancer Research</i> , 2008, 10, R86.	5.0	107
105	IGF-1, IGFBP-1, and IGFBP-3 Polymorphisms Predict Circulating IGF Levels but Not Breast Cancer Risk: Findings from the Breast and Prostate Cancer Cohort Consortium (BPC3). <i>PLoS ONE</i> , 2008, 3, e2578.	2.5	106
106	Milk consumption and the prepubertal somatotrophic axis. <i>Nutrition Journal</i> , 2007, 6, 28.	3.4	103
107	Genetic Factors Related to Racial Variation in Plasma Levels of Insulin-Like Growth Factor-1: Implications for Premenopausal Breast Cancer Risk. <i>Molecular Genetics and Metabolism</i> , 2001, 72, 144-154.	1.1	101
108	A Prospective Study of Plasma Adiponectin and Pancreatic Cancer Risk in Five US Cohorts. <i>Journal of the National Cancer Institute</i> , 2013, 105, 95-103.	6.3	101

#	ARTICLE	IF	CITATIONS
109	Tamoxifen reduces serum insulin-like growth factor I (IGF-I). <i>Breast Cancer Research and Treatment</i> , 1992, 22, 91-100.	2.5	100
110	Endocrine effects of IGF-I on normal and transformed breast epithelial cells: potential relevance to strategies for breast cancer treatment and prevention. <i>Breast Cancer Research and Treatment</i> , 1998, 47, 209-217.	2.5	100
111	Racial Differences in Premenopausal Endogenous Hormones. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 2147-2153.	2.5	100
112	Metformin in Chemotherapy-naive Castration-resistant Prostate Cancer: A Multicenter Phase 2 Trial (SAKK 08/09). <i>European Urology</i> , 2014, 66, 468-474.	1.9	100
113	High-Fat Diet Accelerates Carcinogenesis in a Mouse Model of Barrett's Esophagus via Interleukin 8 and Alterations to the Gut Microbiome. <i>Gastroenterology</i> , 2019, 157, 492-506.e2.	1.3	100
114	The Effects of Varying Dietary Carbohydrate and Fat Content on Survival in a Murine LNCaP Prostate Cancer Xenograft Model. <i>Cancer Prevention Research</i> , 2009, 2, 557-565.	1.5	98
115	Exercise modulation of the host-tumor interaction in an orthotopic model of murine prostate cancer. <i>Journal of Applied Physiology</i> , 2012, 113, 263-272.	2.5	98
116	Insulin Increases <i>De Novo</i> Steroidogenesis in Prostate Cancer Cells. <i>Cancer Research</i> , 2011, 71, 5754-5764.	0.9	97
117	Anti-diabetic doses of metformin decrease proliferation markers in tumors of patients with endometrial cancer. <i>Gynecologic Oncology</i> , 2014, 134, 607-614.	1.4	97
118	Insulin Receptor Isoform A and Insulin-like Growth Factor II as Additional Treatment Targets in Human Osteosarcoma. <i>Cancer Research</i> , 2009, 69, 2443-2452.	0.9	96
119	Overcoming Drug Development Bottlenecks With Repurposing: Repurposing biguanides to target energy metabolism for cancer treatment. <i>Nature Medicine</i> , 2014, 20, 591-593.	30.7	95
120	Insulinlike Growth Factor I: A Potent Mitogen for Human Osteogenic Sarcoma. <i>Journal of the National Cancer Institute</i> , 1990, 82, 301-305.	6.3	94
121	Expression of insulin-like growth factor receptor, IGF-1, and IGF-2 in primary and metastatic osteosarcoma. <i>Journal of Surgical Oncology</i> , 1998, 69, 21-27.	1.7	94
122	Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men. <i>Cancer Research</i> , 2003, 63, 3991-4.	0.9	94
123	Prediagnostic Plasma C-Peptide and Pancreatic Cancer Risk in Men and Women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007, 16, 2101-2109.	2.5	93
124	Insulin-like growth factor-binding protein-3 inhibition of prostate cancer growth involves suppression of angiogenesis. <i>Oncogene</i> , 2007, 26, 1811-1819.	5.9	93
125	Long-term effects of insulin glargine on the risk of breast cancer. <i>Diabetologia</i> , 2011, 54, 2254-2262.	6.3	93
126	Integrated Pharmacodynamic Analysis Identifies Two Metabolic Adaption Pathways to Metformin in Breast Cancer. <i>Cell Metabolism</i> , 2018, 28, 679-688.e4.	16.2	92

#	ARTICLE	IF	CITATIONS
127	Vitamin D and Calcium Intakes from Food or Supplements and Mammographic Breast Density. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 1653-1659.	2.5	91
128	Targeting insulin and insulin-like growth factor signalling in oncology. <i>Current Opinion in Pharmacology</i> , 2008, 8, 384-392.	3.5	90
129	The Insulin Receptor/Insulin-Like Growth Factor Receptor Family as a Therapeutic Target in Oncology. <i>Clinical Cancer Research</i> , 2012, 18, 40-50.	7.0	89
130	Antiproliferative Action of Vitamin D-Related Compounds and Insulin-Like Growth Factor-Binding Protein 5 Accumulation. <i>Journal of the National Cancer Institute</i> , 1997, 89, 652-656.	6.3	88
131	Insulin, insulin-like growth factors and neoplasia. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2008, 22, 625-638.	4.7	85
132	Vitamin D Status in Patients With Stage IV Colorectal Cancer: Findings From Intergroup Trial N9741. <i>Journal of Clinical Oncology</i> , 2011, 29, 1599-1606.	1.6	85
133	A sequence repeat in the insulin-like growth factor-1 gene and risk of breast cancer. <i>International Journal of Cancer</i> , 2002, 100, 332-336.	5.1	84
134	Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours. <i>Breast Cancer Research</i> , 2005, 7, R796-807.	5.0	83
135	Randomized Trial of Tamoxifen Versus Combined Tamoxifen and Octreotide LAR Therapy in the Adjuvant Treatment of Early-Stage Breast Cancer in Postmenopausal Women: NCIC CTG MA.14. <i>Journal of Clinical Oncology</i> , 2011, 29, 3869-3876.	1.6	83
136	Pharmacodynamic and Antineoplastic Activity of BI 836845, a Fully Human IGF Ligand-Neutralizing Antibody, and Mechanistic Rationale for Combination with Rapamycin. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 399-409.	4.1	83
137	Genomewide meta-analysis identifies loci associated with IGF and IGFBP levels with impact on age-related traits. <i>Aging Cell</i> , 2016, 15, 811-824.	6.7	83
138	Insulin-like Growth Factors and Prostate Cancer. <i>Epidemiologic Reviews</i> , 2001, 23, 59-66.	3.5	82
139	Whole Milk Intake Is Associated with Prostate Cancer-Specific Mortality among U.S. Male Physicians. <i>Journal of Nutrition</i> , 2013, 143, 189-196.	2.9	82
140	Serum concentrations of IGF-I, IGFBP-3 and c-peptide and risk of hyperplasia and cancer of the breast in postmenopausal women. <i>International Journal of Cancer</i> , 2004, 108, 773-779.	5.1	81
141	C-Reactive Protein Concentrations and Subsequent Ovarian Cancer Risk. <i>Obstetrics and Gynecology</i> , 2007, 109, 933-941.	2.4	80
142	Relevance of the OCT1 transporter to the antineoplastic effect of biguanides. <i>Biochemical and Biophysical Research Communications</i> , 2011, 414, 694-699.	2.1	80
143	Modification of the Association Between Obesity and Lethal Prostate Cancer by TMPRSS2:ERG. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1881-1890.	6.3	80
144	Metformin and Rapamycin Reduce Pancreatic Cancer Growth in Obese Prediabetic Mice by Distinct MicroRNA-Regulated Mechanisms. <i>Diabetes</i> , 2015, 64, 1632-1642.	0.6	80

#	ARTICLE	IF	CITATIONS
145	Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab. <i>British Journal of Cancer</i> , 2011, 104, 68-74.	6.4	79
146	The effects of metformin on gut microbiota and the immune system as research frontiers. <i>Diabetologia</i> , 2017, 60, 1662-1667.	6.3	79
147	Menopause Is a Determinant of Breast Aromatase Expression and Its Associations With BMI, Inflammation, and Systemic Markers. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 1692-1701.	3.6	77
148	Amplified, overexpressed and rearranged epidermal growth factor receptor gene in a human astrocytoma cell line. <i>Biochemical and Biophysical Research Communications</i> , 1985, 131, 207-215.	2.1	76
149	Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome. <i>Annals of Oncology</i> , 2000, 11, 307-314.	1.2	76
150	Prediagnostic plasma IGF-1, IGF-1 and risk of prostate cancer. <i>International Journal of Cancer</i> , 2015, 136, 2418-2426.	5.1	76
151	Association of markers of insulin and glucose control with subsequent colorectal cancer risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2003, 12, 412-8.	2.5	76
152	Polymorphic variation at the -202 locus in IGF-1: Influence on serum levels of insulin-like growth factors, interaction with plasma retinol and vitamin D and breast cancer risk. <i>International Journal of Cancer</i> , 2003, 107, 60-64.	5.1	75
153	Overcoming Trastuzumab Resistance in HER2-Overexpressing Breast Cancer Cells by Using a Novel Celecoxib-Derived Phosphoinositide-Dependent Kinase-1 Inhibitor. <i>Molecular Pharmacology</i> , 2006, 70, 1534-1541.	2.3	74
154	The Use of Metformin and the Incidence of Lung Cancer in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2013, 36, 124-129.	8.6	74
155	C-Peptide, Insulin-like Growth Factor Binding Protein-1, Glycosylated Hemoglobin, and the Risk of Distal Colorectal Adenoma in Women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 750-755.	2.5	73
156	Somatic point mutations occurring early in development: a monozygotic twin study. <i>Journal of Medical Genetics</i> , 2014, 51, 28-34.	3.2	73
157	Characterization of insulin-like growth factor I (IGF-I) receptors of human breast cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 1988, 154, 326-331.	2.1	71
158	Dietary Feeding of Silibinin Inhibits Prostate Tumor Growth and Progression in Transgenic Adenocarcinoma of the Mouse Prostate Model. <i>Cancer Research</i> , 2007, 67, 11083-11091.	0.9	71
159	Circulating Insulin-Like Growth Factor Binding Protein-1 and the Risk of Pancreatic Cancer. <i>Cancer Research</i> , 2007, 67, 7923-7928.	0.9	71
160	Insulin-Like Growth Factor Binding Protein-2 Is a Novel Therapeutic Target Associated with Breast Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 6944-6954.	7.0	71
161	Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells. <i>Medical Science Monitor</i> , 2002, 8, BR521-6.	1.1	71
162	Prediagnostic Adiponectin Concentrations and Pancreatic Cancer Risk in Male Smokers. <i>American Journal of Epidemiology</i> , 2008, 168, 1047-1055.	3.4	70

#	ARTICLE	IF	CITATIONS
163	A prospective study of plasma levels of insulin-like growth factor I (IGF-I) and IGF-binding protein-3, and colorectal cancer risk among men. <i>Growth Hormone and IGF Research</i> , 2000, 10, S28-S29.	1.1	69
164	Serum IGF-I, IGF-II, IGFBP-3, and IGF-I/IGFBP-3 Molar Ratio and Risk of Pancreatic Cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 2298-2306.	2.5	69
165	Silibinin suppresses in vivo growth of human prostate carcinoma PC-3 tumor xenograft. <i>Carcinogenesis</i> , 2007, 28, 2567-2574.	2.8	68
166	Circulating Insulin and C-Peptide Levels and Risk of Breast Cancer among Predominately Premenopausal Women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007, 16, 161-164.	2.5	67
167	A genome-wide association study identifies novel loci associated with circulating IGF-I and IGFBP-3. <i>Human Molecular Genetics</i> , 2011, 20, 1241-1251.	2.9	67
168	Insulin-like Growth Factor Binding Protein 3 (IGF-BP3) Inhibits Estrogen-Stimulated Breast Cancer Cell Proliferation. <i>Biochemical and Biophysical Research Communications</i> , 1994, 198, 292-297.	2.1	66
169	Insulin-like growth factor receptor I targeting in epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2006, 100, 389-396.	1.4	66
170	Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era. <i>Cancer Causes and Control</i> , 2005, 16, 255-262.	1.8	65
171	Common genetic variation in IGF1, IGFBP-1, and IGFBP-3 in relation to mammographic density: a cross-sectional study. <i>Breast Cancer Research</i> , 2007, 9, R18.	5.0	65
172	Insulin-like growth factor-(IGF)-axis, inflammation, and glucose intolerance among older adults. <i>Growth Hormone and IGF Research</i> , 2008, 18, 166-173.	1.1	65
173	Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial. <i>Breast Cancer Research and Treatment</i> , 2014, 148, 81-90.	2.5	65
174	Insulin, insulin-like growth factors, insulin resistance, and neoplasia. <i>American Journal of Clinical Nutrition</i> , 2007, 86, 820S-822S.	4.7	64
175	eIF4A supports an oncogenic translation program in pancreatic ductal adenocarcinoma. <i>Nature Communications</i> , 2019, 10, 5151.	12.8	64
176	Body shape throughout life and correlations with IGFs and GH. <i>Endocrine-Related Cancer</i> , 2007, 14, 721-732.	3.1	62
177	Safety, Pharmacokinetics, and Pharmacodynamics of the Insulin-Like Growth Factor Type 1 Receptor Inhibitor Figitumumab (CP-751,871) in Combination with Paclitaxel and Carboplatin. <i>Journal of Thoracic Oncology</i> , 2009, 4, 1397-1403.	1.1	62
178	Body Size in Early Life and Adult Levels of Insulin-like Growth Factor 1 and Insulin-like Growth Factor Binding Protein 3. <i>American Journal of Epidemiology</i> , 2011, 174, 642-651.	3.4	62
179	Diabetes and breast cancer among women with <i>BRCA1</i> and <i>BRCA2</i> mutations. <i>Cancer</i> , 2011, 117, 1812-1818.	4.1	62
180	Periprostatic adipose inflammation is associated with high-grade prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2017, 20, 418-423.	3.9	62

#	ARTICLE	IF	CITATIONS
181	Insulin-Like Growth Factors and Neoplasia. Novartis Foundation Symposium, 2008, , 84-107.	1.1	61
182	ETV6-NTRK3-Mediated Breast Epithelial Cell Transformation Is Blocked by Targeting the IGF1R Signaling Pathway. Cancer Research, 2011, 71, 1060-1070.	0.9	61
183	Translational and HIF-1-Dependent Metabolic Reprogramming Underpin Metabolic Plasticity and Responses to Kinase Inhibitors and Biguanides. Cell Metabolism, 2018, 28, 817-832.e8.	16.2	61
184	Circulating insulin-like growth factor axis and the risk of pancreatic cancer in four prospective cohorts. British Journal of Cancer, 2007, 97, 98-104.	6.4	60
185	Metabolic syndrome components and colorectal adenoma in the CLUE II cohort. Cancer Causes and Control, 2010, 21, 1-10.	1.8	59
186	Low dose octreotide and tamoxifen in the treatment of adenocarcinoma of the pancreas. Cancer, 1995, 75, 23-28.	4.1	58
187	A germ line mutation that delays prostate cancer progression and prolongs survival in a murine prostate cancer model. Oncogene, 2005, 24, 4736-4740.	5.9	58
188	Genetic Polymorphisms Involved in Insulin-like Growth Factor (IGF) Pathway in Relation to Mammographic Breast Density and IGF Levels. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 880-888.	2.5	58
189	Synthetic Lethality Screens Reveal RPS6 and MST1R as Modifiers of Insulin-like Growth Factor-1 Receptor Inhibitor Activity in Childhood Sarcomas. Cancer Research, 2010, 70, 8770-8781.	0.9	58
190	A prospective study of circulating adipokine levels and risk of multiple myeloma. Blood, 2012, 120, 4418-4420.	1.4	58
191	Elevated Bone Turnover Predicts for Bone Metastasis in Postmenopausal Breast Cancer: Results of NCIC CTG MA.14. Journal of Clinical Oncology, 2011, 29, 3605-3610.	1.6	57
192	Serum leptin and adiponectin levels and risk of renal cell carcinoma. Obesity, 2013, 21, 1478-1485.	3.0	57
193	Plasma IGF-I levels and cognitive performance in older women. Neurobiology of Aging, 2007, 28, 135-142.	3.1	56
194	Type 2 diabetes and the risk of mortality among patients with prostate cancer. Cancer Causes and Control, 2014, 25, 329-338.	1.8	56
195	A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma. , 1999, 85, 1284-1292.		55
196	Influence of Insulin-like Growth Factors on the Strength of the Relation of Vitamin D and Calcium Intakes to Mammographic Breast Density. Cancer Research, 2006, 66, 588-597.	0.9	55
197	Clinical Development of Inhibitors of the Insulin-like Growth Factor Receptor in Oncology. Current Drug Targets, 2009, 10, 923-936.	2.1	55
198	The Use of Metformin and Colorectal Cancer Incidence in Patients with Type II Diabetes Mellitus. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 1877-1883.	2.5	55

#	ARTICLE	IF	CITATIONS
199	Lifestyle correlates of plasma insulin-like growth factor I and insulin-like growth factor binding protein 3 concentrations. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2002, 11, 862-7.	2.5	55
200	Insulin-like growth factor-1, insulin-like growth factor binding protein-3 and risk of benign prostate hyperplasia in the prostate cancer prevention trial. <i>Prostate</i> , 2008, 68, 1477-1486.	2.3	54
201	Higher circulating levels of IGF-1 are associated with longer leukocyte telomere length in healthy subjects. <i>Mechanisms of Ageing and Development</i> , 2009, 130, 771-776.	4.6	54
202	Effects of Rapid Weight Loss on Systemic and Adipose Tissue Inflammation and Metabolism in Obese Postmenopausal Women. <i>Journal of the Endocrine Society</i> , 2017, 1, 625-637.	0.2	54
203	Insulin-Like Growth Factor-Related Signaling and Cancer Development. , 2007, 174, 49-53.		54
204	Enhancement of Tamoxifen-Induced Suppression of Insulin-Like Growth Factor I Gene Expression and Serum Level by a Somatostatin Analogue. <i>Biochemical and Biophysical Research Communications</i> , 1994, 203, 253-259.	2.1	52
205	Plasma Insulin-like Growth Factors, Insulin-like Binding Protein-3, and Outcome in Metastatic Colorectal Cancer: Results from Intergroup Trial N9741. <i>Clinical Cancer Research</i> , 2008, 14, 8263-8269.	7.0	52
206	PTEN-induction in U251 glioma cells decreases the expression of insulin-like growth factor binding protein-2. <i>Biochemical and Biophysical Research Communications</i> , 2005, 336, 1056-1061.	2.1	51
207	Serum IGF1, IGF2 and IGFBP3 and risk of advanced colorectal adenoma. <i>International Journal of Cancer</i> , 2012, 131, E105-13.	5.1	51
208	Common Polymorphisms in the Adiponectin and Its Receptor Genes, Adiponectin Levels and the Risk of Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 2618-2627.	2.5	50
209	Circulating Leptin and Risk of Pancreatic Cancer: A Pooled Analysis From 3 Cohorts. <i>American Journal of Epidemiology</i> , 2015, 182, 187-197.	3.4	50
210	Synchronized Seasonal Variations of Mammographic Breast Density and Plasma 25-Hydroxyvitamin D. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007, 16, 929-933.	2.5	49
211	Hypoxia-inducible factor-1 \pm (HIF-1 \pm) gene polymorphisms, circulating insulin-like growth factor binding protein (IGFBP)-3 levels and prostate cancer. <i>Prostate</i> , 2007, 67, 1354-1361.	2.3	49
212	Total Insulinlike Growth Factor 1 and Insulinlike Growth Factor Binding Protein Levels, Functional Status, and Mortality in Older Adults. <i>Journal of the American Geriatrics Society</i> , 2008, 56, 652-660.	2.6	48
213	IGF2 increases de novo steroidogenesis in prostate cancer cells. <i>Endocrine-Related Cancer</i> , 2013, 20, 173-186.	3.1	48
214	Obesity-related hormones and endometrial cancer among postmenopausal women: a nested case-control study within the B $\frac{1}{4}$ FIT cohort. <i>Endocrine-Related Cancer</i> , 2013, 20, 151-160.	3.1	48
215	Uncoupling Hepatic Oxidative Phosphorylation Reduces Tumor Growth in Two Murine Models of Colon Cancer. <i>Cell Reports</i> , 2018, 24, 47-55.	6.4	48
216	Hormonal profile of diabetic men and the potential link to prostate cancer. <i>Cancer Causes and Control</i> , 2008, 19, 703-710.	1.8	47

#	ARTICLE	IF	CITATIONS
217	A comprehensive analysis of common IGF1, IGFBP1 and IGFBP3 genetic variation with prospective IGF-I and IGFBP-3 blood levels and prostate cancer risk among Caucasians. Human Molecular Genetics, 2010, 19, 3089-3101.	2.9	47
218	A Phase II Pharmacodynamic Study of Preoperative Figitumumab in Patients with Localized Prostate Cancer. Clinical Cancer Research, 2012, 18, 3407-3413.	7.0	47
219	Targeting Oxidative Phosphorylation: Why, When, and How. Cancer Cell, 2013, 23, 263-264.	16.8	47
220	5' sense and antisense transgenes modify insulin-like growth factor-I mRNA levels. FEBS Journal, 2000, 267, 4020-4027.	0.2	46
221	Serum Insulin-like Growth Factor I and Subsequent Risk of Colorectal Cancer among Japanese-American Men. American Journal of Epidemiology, 2003, 158, 424-431.	3.4	46
222	IGFBP-2 expression in MCF-7 cells is regulated by the PI3K/AKT/mTOR pathway through Sp1-induced increase in transcription. Growth Factors, 2010, 28, 243-255.	1.7	46
223	A prospective study of intakes of zinc and heme iron and colorectal cancer risk in men and women. Cancer Causes and Control, 2011, 22, 1627-1637.	1.8	46
224	Pancreatic Cancer Risk Associated with Prediagnostic Plasma Levels of Leptin and Leptin Receptor Genetic Polymorphisms. Cancer Research, 2016, 76, 7160-7167.	0.9	46
225	Insulin-like growth factor I (IGF-I), IGF-binding protein-3 and the risk of colorectal adenoma and cancer in the Nurses' Health Study. Growth Hormone and IGF Research, 2000, 10, S30-S31.	1.1	45
226	Co-targeting IGF-1R and c-kit: synergistic inhibition of proliferation and induction of apoptosis in H 209 small cell lung cancer cells. British Journal of Cancer, 2004, 90, 1825-1829.	6.4	45
227	Current Status and Challenges Associated with Targeting mTOR for Cancer Therapy. BioDrugs, 2009, 23, 77-91.	4.6	45
228	Genetic variation and circulating levels of IGF-I and IGFBP-3 in relation to risk of proliferative benign breast disease. International Journal of Cancer, 2010, 126, 180-190.	5.1	45
229	Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium. Human Molecular Genetics, 2010, 19, 3873-3884.	2.9	45
230	Effect of intermittent fasting on prostate cancer tumor growth in a mouse model. Prostate Cancer and Prostatic Diseases, 2010, 13, 350-355.	3.9	45
231	Suppression of serum insulin-like growth factor-1 levels in breast cancer patients during adjuvant tamoxifen therapy. European Journal of Cancer, 1993, 29, 1368-1372.	2.8	44
232	Insulin analogues and cancer risk: cause for concern or cause célèbre?. International Journal of Clinical Practice, 2010, 64, 628-636.	1.7	43
233	Pregnancy-Associated Plasma Protein-A (PAPP-A) in Ewing Sarcoma: Role in Tumor Growth and Immune Evasion. Journal of the National Cancer Institute, 2019, 111, 970-982.	6.3	43
234	Activity and Safety of the Antiestrogen EM-800, the Orally Active Precursor of Acolbifene, in Tamoxifen-Resistant Breast Cancer. Journal of Clinical Oncology, 2004, 22, 864-871.	1.6	42

#	ARTICLE	IF	CITATIONS
235	Glycemic load effect on fasting and post-prandial serum glucose, insulin, IGF-1 and IGFBP-3 in a randomized, controlled feeding study. <i>European Journal of Clinical Nutrition</i> , 2012, 66, 1146-1152.	2.9	42
236	Prediagnostic circulating adipokine concentrations and risk of renal cell carcinoma in male smokers. <i>Carcinogenesis</i> , 2013, 34, 109-112.	2.8	42
237	Fasting Insulin Levels and Cognitive Decline in Older Women without Diabetes. <i>Neuroepidemiology</i> , 2008, 30, 174-179.	2.3	41
238	Prediagnosis biomarkers of insulin-like growth factor-1, insulin, and interleukin-6 dysregulation and multiple myeloma risk in the Multiple Myeloma Cohort Consortium. <i>Blood</i> , 2012, 120, 4929-4937.	1.4	41
239	Protein Expression of PTEN, Insulin-Like Growth Factor I Receptor (IGF-IR), and Lethal Prostate Cancer: A Prospective Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 1984-1993.	2.5	41
240	Castration-Induced Apoptosis in the Rat Ventral Prostate Is Associated with Increased Expression of Genes Encoding Insulin-Like Growth Factor Binding Proteins 2, 3, 4 and 5. <i>Endocrinology</i> , 1998, 139, 807-810.	2.8	41
241	Metformin, aging and cancer. <i>Aging</i> , 2013, 5, 330-331.	3.1	41
242	Direct effects of tamoxifen on growth hormone secretion by pituitary cells in vitro. <i>European Journal of Cancer</i> , 1992, 28, 788-793.	2.8	40
243	Racial Variation in Sex Steroid Hormones and the Insulin-Like Growth Factor Axis in Umbilical Cord Blood of Male Neonates. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 1484-1491.	2.5	40
244	Protective effect of metformin in CD1 mice placed on a high carbohydrate high fat diet. <i>Biochemical and Biophysical Research Communications</i> , 2010, 397, 537-542.	2.1	40
245	The Use of Metformin in Patients with Prostate Cancer and the Risk of Death. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 2111-2118.	2.5	40
246	Long-Term Use of Long-Acting Insulin Analogs and Breast Cancer Incidence in Women With Type 2 Diabetes. <i>Journal of Clinical Oncology</i> , 2017, 35, 3647-3653.	1.6	40
247	Bicalutamide (Casodex)-induced prostate regression involves increased expression of genes encoding insulin-like growth factor binding proteins. <i>Urology</i> , 1999, 54, 1120-1125.	1.0	39
248	Insulin-like growth factor I (IGF-I), IGF-binding protein-3 and prostate cancer risk: epidemiological studies. <i>Growth Hormone and IGF Research</i> , 2000, 10, S32-S33.	1.1	39
249	Genetic Variants, Prediagnostic Circulating Levels of Insulin-like Growth Factors, Insulin, and Glucose and the Risk of Colorectal Cancer: The Multiethnic Cohort Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 810-820.	2.5	39
250	Carbon Source and Myc Expression Influence the Antiproliferative Actions of Metformin. <i>Cancer Research</i> , 2012, 72, 6257-6267.	0.9	39
251	Inhibiting mitochondrial respiration prevents cancer in a mouse model of Li-Fraumeni syndrome. <i>Journal of Clinical Investigation</i> , 2016, 127, 132-136.	8.2	39
252	IGF1R Derived PI3K/AKT Signaling Maintains Growth in a Subset of Human T-Cell Acute Lymphoblastic Leukemias. <i>PLoS ONE</i> , 2016, 11, e0161158.	2.5	39

#	ARTICLE	IF	CITATIONS
253	Metformin abolishes increased tumor 18F-2-fluoro-2-deoxy-D-glucose uptake associated with a high energy diet. <i>Cell Cycle</i> , 2011, 10, 2770-2778.	2.6	38
254	Insulin-like Growth Factors and Ovarian Cancer Risk: A Nested Case-Control Study in Three Cohorts. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007, 16, 1691-1695.	2.5	37
255	Evidence for a tumor promoting effect of high-fat diet independent of insulin resistance in HER2/Neu mammary carcinogenesis. <i>Breast Cancer Research and Treatment</i> , 2010, 122, 647-659.	2.5	37
256	Prediagnosis Plasma Adiponectin in Relation to Colorectal Cancer Risk According to KRAS Mutation Status. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv363.	6.3	37
257	Insulin-like growth factors and neoplasia. <i>Novartis Foundation Symposium</i> , 2004, 262, 84-98; discussion 98-107, 265-8.	1.1	37
258	Phase II Randomized Study of Figitumumab plus Docetaxel and Docetaxel Alone with Crossover for Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 1925-1934.	7.0	36
259	Insulin, glucose and the increased risk of cancer in patients with type 2 diabetes. <i>Diabetologia</i> , 2010, 53, 2086-2088.	6.3	35
260	A dietary pattern that is associated with C-peptide and risk of colorectal cancer in women. <i>Cancer Causes and Control</i> , 2012, 23, 959-965.	1.8	35
261	Inhibiting stemness and invasive properties of glioblastoma tumorsphere by combined treatment with temozolomide and a newly designed biguanide (HL156A). <i>Oncotarget</i> , 2016, 7, 65643-65659.	1.8	35
262	Expression of IGF/insulin receptor in prostate cancer tissue and progression to lethal disease. <i>Carcinogenesis</i> , 2018, 39, 1431-1437.	2.8	35
263	Do Cancer Cells Care If Their Host Is Hungry?. <i>Cell Metabolism</i> , 2009, 9, 401-403.	16.2	34
264	Androgens, growth factors, and risk of prostate cancer: The Multiethnic Cohort. <i>Prostate</i> , 2010, 70, 906-915.	2.3	33
265	Finasteride Modifies the Relation between Serum C-Peptide and Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial. <i>Cancer Prevention Research</i> , 2010, 3, 279-289.	1.5	33
266	Plasma C-Peptide, Mammographic Breast Density, and Risk of Invasive Breast Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 1786-1796.	2.5	33
267	Insulin-like Growth Factor Pathway Genetic Polymorphisms, Circulating IGF1 and IGFBP3, and Prostate Cancer Survival. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju085.	6.3	33
268	Insulin-like growth factor-I antagonizes the antiproliferative effects of cyclooxygenase-2 inhibitors on BxPC-3 pancreatic cancer cells. <i>Cancer Research</i> , 2002, 62, 7372-6.	0.9	33
269	Tissue-Specific Targeting of the Pthrp Gene: The Generation of Mice with Floxed Alleles*. <i>Endocrinology</i> , 2001, 142, 2070-2077.	2.8	32
270	Premenopausal levels of circulating insulin-like growth factor I and the risk of postmenopausal breast cancer. <i>International Journal of Cancer</i> , 2006, 118, 1279-1284.	5.1	32

#	ARTICLE	IF	CITATIONS
271	Interactions between Plasma Levels of 25-Hydroxyvitamin D, Insulin-Like Growth Factor (IGF)-1 and C-Peptide with Risk of Colorectal Cancer. PLoS ONE, 2011, 6, e28520.	2.5	32
272	Post-diagnostic use of beta-blockers and the risk of death in patients with prostate cancer. European Journal of Cancer, 2014, 50, 2838-2845.	2.8	32
273	5 α -Reductase Inhibitors and the Risk of Cancer-Related Mortality in Men With Prostate Cancer. JAMA Oncology, 2015, 1, 314.	7.1	32
274	Serum insulin-like growth factor (IGF) and IGF-binding protein levels and risk of lung cancer: a case-control study nested in the beta-Carotene and Retinol Efficacy Trial Cohort. Cancer Epidemiology Biomarkers and Prevention, 2002, 11, 1413-8.	2.5	32
275	The Human Mammary-Derived Growth Inhibitor (MDGI) Gene: Genomic Structure and Mutation Analysis in Human Breast Tumors. Genomics, 1996, 34, 63-68.	2.9	31
276	Plasma insulin-like growth factor 1 is positively associated with low-grade prostate cancer in the Health Professionals Follow-up Study 1993-2004. International Journal of Cancer, 2011, 128, 660-667.	5.1	31
277	IGF1/insulin receptor kinase inhibition by BMS-536924 is better tolerated than alloxan-induced hypoinsulinemia and more effective than metformin in the treatment of experimental insulin-responsive breast cancer. Endocrine-Related Cancer, 2011, 18, 699-709.	3.1	31
278	Metformin and Pancreatic Cancer: A Clue Requiring Investigation. Clinical Cancer Research, 2012, 18, 2723-2725.	7.0	31
279	Assessment of osteopontin in early breast cancer: correlative study in a randomised clinical trial. Breast Cancer Research, 2014, 16, R8.	5.0	31
280	Overexpression of ErbB2 receptor inhibits IGF-I-induced Shc-MAPK signaling pathway in breast cancer cells. Biochemical and Biophysical Research Communications, 2004, 313, 709-715.	2.1	30
281	Growth inhibition of breast epithelial cells by celecoxib is associated with upregulation of insulin-like growth factor binding protein-3 expression. Biochemical and Biophysical Research Communications, 2004, 316, 421-428.	2.1	30
282	High insulinlike growth factor binding protein 1 level predicts incident congestive heart failure in the elderly. American Heart Journal, 2008, 155, 1006-1012.	2.7	30
283	Low Levels of Circulating Adiponectin Are Associated with Multiple Myeloma Risk in Overweight and Obese Individuals. Cancer Research, 2016, 76, 1935-1941.	0.9	30
284	Reduced growth of human sarcoma xenografts in hosts homozygous for the lit mutation. Journal of Surgical Oncology, 2002, 81, 75-79.	1.7	29
285	The hedgehog pathway inhibitor cyclopamine increases levels of p27, and decreases both expression of IGF-II and activation of Akt in PC-3 prostate cancer cells. Cancer Letters, 2007, 255, 300-306.	7.2	29
286	Insulin-like growth factor-1, insulin-like growth factor-binding protein-3, growth hormone, and mammographic density in the Nurses' Health Studies. Breast Cancer Research and Treatment, 2012, 136, 805-812.	2.5	29
287	Alterations in Cellular Energy Metabolism Associated with the Antiproliferative Effects of the ATM Inhibitor KU-55933 and with Metformin. PLoS ONE, 2012, 7, e49513.	2.5	29
288	IGF-I Physiology and Breast Cancer. Recent Results in Cancer Research, 1998, 152, 63-70.	1.8	29

#	ARTICLE	IF	CITATIONS
289	Treatment with Insulin Analog X10 and IGF-1 Increases Growth of Colon Cancer Allografts. <i>PLoS ONE</i> , 2013, 8, e79710.	2.5	29
290	Comprehensive assessment of candidate genes and serological markers for the detection of prostate cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2003, 12, 1429-37.	2.5	29
291	Challenges to cancer control by screening. <i>Nature Reviews Cancer</i> , 2003, 3, 297-303.	28.4	28
292	Serum Insulin-Like Growth Factor-I Levels and Prostatic Intraepithelial Neoplasia: A Clue to the Relationship Between IGF-I Physiology and Prostate Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 1270-1273.	2.5	28
293	BMS-536924 sensitizes human epithelial ovarian cancer cells to the PARP inhibitor, 3-aminobenzamide. <i>Gynecologic Oncology</i> , 2009, 115, 193-198.	1.4	28
294	Inflammatory Plasma Markers and Pancreatic Cancer Risk: A Prospective Study of Five U.S. Cohorts. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 855-861.	2.5	28
295	Insulin-Like Growth Factors and Insulin-Like Growth Factor-1 Binding Proteins and Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial. <i>Cancer Prevention Research</i> , 2013, 6, 91-99.	1.5	28
296	Transcriptomic analysis of human primary breast cancer identifies fatty acid oxidation as a target for metformin. <i>British Journal of Cancer</i> , 2020, 122, 258-265.	6.4	28
297	Loss of function of PTEN alters the relationship between glucose concentration and cell proliferation, increases glycolysis, and sensitizes cells to 2-deoxyglucose. <i>Cancer Letters</i> , 2010, 289, 246-253.	7.2	27
298	Association of C-peptide and leptin with prostate cancer incidence in the Health Professionals Follow-up Study. <i>Cancer Causes and Control</i> , 2014, 25, 625-632.	1.8	27
299	Phosphodiesterase Type 5 Inhibitors and the Risk of Melanoma Skin Cancer. <i>European Urology</i> , 2016, 70, 808-815.	1.9	27
300	Centralized Blood Processing for the Selenium and Vitamin E Cancer Prevention Trial: Effects of Delayed Processing on Carotenoids, Tocopherols, Insulin-Like Growth Factor-I, Insulin-Like Growth Factor Binding Protein 3, Steroid Hormones, and Lymphocyte Viability. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 727-730.	2.5	26
301	Prostate Cancer Risk in Relation to Insulin-like Growth Factor (IGF)-I and IGF-Binding Protein-3: A Prospective Multiethnic Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 252-254.	2.5	26
302	Insulin-like growth factors and risk of kidney cancer in men. <i>British Journal of Cancer</i> , 2010, 103, 132-135.	6.4	26
303	Serum C-Reactive Protein and Risk of Pancreatic Cancer in Two Nested, Case-Control Studies. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 359-369.	2.5	26
304	Metastatic Breast Carcinoma-Associated Fibroblasts Have Enhanced Protumorigenic Properties Related to Increased IGF2 Expression. <i>Clinical Cancer Research</i> , 2019, 25, 7229-7242.	7.0	26
305	Fasting Plasma Insulin, C-Peptide and Cognitive Change in Older Men without Diabetes: Results from the Physicians' Health Study II. <i>Neuroepidemiology</i> , 2010, 34, 200-207.	2.3	25
306	The Use of Aspirin and the Risk of Mortality in Patients with Prostate Cancer. <i>Journal of Urology</i> , 2015, 193, 1220-1225.	0.4	25

#	ARTICLE	IF	CITATIONS
307	Vertex balding, plasma insulin-like growth factor 1, and insulin-like growth factor binding protein 3. <i>Journal of the American Academy of Dermatology</i> , 2000, 42, 1003-1007.	1.2	24
308	Insulin-like Growth Factor-I and Risk of High-Grade Cervical Intraepithelial Neoplasia. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007, 16, 716-722.	2.5	24
309	Glioma Risk in Relation to Serum Levels of Insulin-Like Growth Factors. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007, 16, 844-846.	2.5	24
310	Plasma C-peptide levels and rates of cognitive decline in older, community-dwelling women without diabetes. <i>Psychoneuroendocrinology</i> , 2008, 33, 455-461.	2.7	24
311	The Interactions between Insulin and Androgens in Progression to Castrate-Resistant Prostate Cancer. <i>Advances in Urology</i> , 2012, 2012, 1-11.	1.3	24
312	STAT1 potentiates oxidative stress revealing a targetable vulnerability that increases phenformin efficacy in breast cancer. <i>Nature Communications</i> , 2021, 12, 3299.	12.8	24
313	A hydride transfer complex reprograms NAD metabolism and bypasses senescence. <i>Molecular Cell</i> , 2021, 81, 3848-3865.e19.	9.7	24
314	HH2A, an immortalized bovine mammary epithelial cell line, expresses the gene encoding mammary derived growth inhibitor (MDGI). <i>In Vitro Cellular and Developmental Biology - Animal</i> , 1995, 31, 25-29.	1.5	23
315	Lycopene in the treatment of prostate cancer. <i>Pure and Applied Chemistry</i> , 2002, 74, 1443-1450.	1.9	23
316	Insulin-Like Growth Factors and Leukocyte Telomere Length: The Cardiovascular Health Study. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2009, 64A, 1103-1106.	3.6	23
317	Effects of castration on insulin levels and glucose tolerance in the mouse differ from those in man. <i>Prostate</i> , 2010, 70, 1628-1635.	2.3	23
318	Impact of Addition of Metformin to Abiraterone in Metastatic Castration-Resistant Prostate Cancer Patients With Disease Progressing While Receiving Abiraterone Treatment (MetAb-Pro): Phase 2 Pilot Study. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e323-e328.	1.9	23
319	Insulin-Like Growth Factor-1 and Insulin-Like Growth Factor Binding Protein-3 for Prostate Cancer Detection in Patients Undergoing Prostate Biopsy. <i>Journal of Urology</i> , 2002, 168, 2426-2430.	0.4	22
320	Decline in Circulating Insulin-Like Growth Factors and Mortality in Older Adults: Cardiovascular Health Study All-Stars Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 1970-1976.	3.6	22
321	Exercise and Prostate Cancer: Evidence and Proposed Mechanisms for Disease Modification. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 1281-1288.	2.5	22
322	Insulin-like growth factor (IGF)-1, IGF-binding protein-3, and pancreatic cancer in male smokers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2004, 13, 438-44.	2.5	22
323	A polymorphic locus in the promoter region of the IGFBP3 gene is related to mammographic breast density. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2004, 13, 573-82.	2.5	22
324	Insulin-like growth factor physiology and neoplasia. <i>Growth Hormone and IGF Research</i> , 2000, 10, S6-S7.	1.1	21

#	ARTICLE	IF	CITATIONS
325	Specimen processing time and measurement of total insulin-like growth factor-I (IGF-I), free IGF-I, and IGF binding protein-3 (IGFBP-3). <i>Growth Hormone and IGF Research</i> , 2006, 16, 86-92.	1.1	21
326	Relation of insulin-like growth factor (IGF) I and IGF-binding protein 3 concentrations with intakes of fruit, vegetables, and antioxidants. <i>American Journal of Clinical Nutrition</i> , 2006, 84, 1518-1526.	4.7	21
327	Plasma Insulinlike Growth Factor 1 and Binding-Protein 3 and Risk of Myocardial Infarction in Women: A Prospective Study. <i>Clinical Chemistry</i> , 2008, 54, 1682-1688.	3.2	21
328	A Phase IIa Trial of Metformin for Colorectal Cancer Risk Reduction among Individuals with History of Colorectal Adenomas and Elevated Body Mass Index. <i>Cancer Prevention Research</i> , 2020, 13, 203-212.	1.5	21
329	Metformin requires 4E-BPs to induce apoptosis and repress translation of Mcl-1 in hepatocellular carcinoma cells. <i>Oncotarget</i> , 2017, 8, 50542-50556.	1.8	21
330	Metformin-induced reductions in tumor growth involves modulation of the gut microbiome. <i>Molecular Metabolism</i> , 2022, 61, 101498.	6.5	21
331	IGF signaling contributes to malignant transformation of hematopoietic progenitors by the MLL-AF9 oncoprotein. <i>Experimental Hematology</i> , 2012, 40, 715-723.e6.	0.4	20
332	Circulating levels of obesity-related markers and risk of renal cell carcinoma in the PLCO cancer screening trial. <i>Cancer Causes and Control</i> , 2017, 28, 801-807.	1.8	20
333	The role of GSK3 in metabolic pathway perturbations in cancer. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2021, 1868, 119059.	4.1	20
334	Serum insulin-like growth factor-I (IGF-I) does not correlate positively with isometric strength, fatigue, and quality of life in post-polio syndrome. <i>Journal of the Neurological Sciences</i> , 2001, 182, 107-115.	0.6	19
335	Circulating Insulin-like Growth Factor (IGF)-I and IGF Binding Protein (IGFBP)-3 Levels and Postmenopausal Breast Cancer Risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) Cohort. <i>Hormones and Cancer</i> , 2010, 1, 100-111.	4.9	19
336	Human prostate cancer xenografts in <i>lit/lit</i> mice exhibit reduced growth and androgen-independent progression. <i>Prostate</i> , 2011, 71, 525-537.	2.3	19
337	A tripartite complex composed of ETV6-NTRK3, IRS1 and IGF1R is required for ETV6-NTRK3-mediated membrane localization and transformation. <i>Oncogene</i> , 2012, 31, 1334-1340.	5.9	19
338	Racial variation in vitamin D cord blood concentration in white and black male neonates. <i>Cancer Causes and Control</i> , 2013, 24, 91-98.	1.8	19
339	Genetic and Circulating Biomarker Data Improve Risk Prediction for Pancreatic Cancer in the General Population. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 999-1008.	2.5	19
340	Fatty acid metabolism in human breast cancer cells (MCF7) transfected with heart-type fatty acid binding protein. <i>Molecular and Cellular Biochemistry</i> , 1999, 199, 41-48.	3.1	18
341	Risk of cancer after growth-hormone treatment. <i>Lancet, The</i> , 2002, 360, 268-269.	13.7	18
342	Associations between Plasma Insulin-Like Growth Factor Proteins and C-Peptide and Quality of Life in Patients with Metastatic Colorectal Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 1402-1410.	2.5	18

#	ARTICLE	IF	CITATIONS
343	Prediagnostic C-Peptide and Risk of Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007, 16, 2164-2165.	2.5	18
344	A profile of impaired insulin degradation in relation to late-life cognitive decline: A preliminary investigation. <i>International Journal of Geriatric Psychiatry</i> , 2009, 24, 177-182.	2.7	18
345	Associations of pregnancy characteristics with maternal and cord steroid hormones, angiogenic factors, and insulin-like growth factor axis. <i>Cancer Causes and Control</i> , 2011, 22, 1587-1595.	1.8	18
346	Magnesium intake, plasma C-peptide, and colorectal cancer incidence in US women: a 28-year follow-up study. <i>British Journal of Cancer</i> , 2012, 106, 1335-1341.	6.4	18
347	Maternal and cord steroid sex hormones, angiogenic factors, and insulin-like growth factor axis in African-American preeclamptic and uncomplicated pregnancies. <i>Cancer Causes and Control</i> , 2012, 23, 779-784.	1.8	18
348	Risk of Breast Cancer by Individual Insulin Use: An International Multicenter Study. <i>Diabetes Care</i> , 2014, 37, 134-143.	8.6	18
349	Quantification of Binding of IGF-1 to BI 836845, a Candidate Therapeutic Antibody Against IGF-1 and IGF-2, and Effects of This Antibody on IGF-1:IGFBP-3 Complexes In Vitro and in Male C57BL/6 Mice. <i>Endocrinology</i> , 2014, 155, 703-715.	2.8	18
350	Circulating insulin-like growth factor-I, insulin-like growth factor binding protein-3 and terminal duct lobular unit involution of the breast: a cross-sectional study of women with benign breast disease. <i>Breast Cancer Research</i> , 2016, 18, 24.	5.0	18
351	Trajectories of IGF-I Predict Mortality in Older Adults: The Cardiovascular Health Study. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2018, 73, 953-959.	3.6	18
352	Perturbations of cancer cell metabolism by the antidiabetic drug canagliflozin. <i>Neoplasia</i> , 2021, 23, 391-399.	5.3	18
353	Clinically Relevant Circulating Protein Biomarkers for Type 1 Diabetes: Evidence From a Two-Sample Mendelian Randomization Study. <i>Diabetes Care</i> , 2022, 45, 169-177.	8.6	18
354	The Human Insulin-like Growth Factor-Binding Protein 4 Gene Maps to Chromosome Region 17q12-q21.1 and Is Close to the Gene for Hereditary Breast-Ovarian Cancer. <i>Genomics</i> , 1993, 18, 414-417.	2.9	17
355	Levels of C-Peptide and Mammographic Breast Density. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 2661-2664.	2.5	17
356	Circulating Adiponectin Levels Differ Between Patients with Multiple Myeloma and its Precursor Disease. <i>Obesity</i> , 2017, 25, 1317-1320.	3.0	17
357	Effect of Exercise or Metformin on Biomarkers of Inflammation in Breast and Colorectal Cancer: A Randomized Trial. <i>Cancer Prevention Research</i> , 2020, 13, 1055-1062.	1.5	17
358	Plasma Levels of Acid-Labile Subunit, Free Insulin-Like Growth Factor-I, and Prostate Cancer Risk: A Prospective Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 484-491.	2.5	16
359	Insulin-like growth factor-1, insulin-like growth factor binding protein-3 and lobule type in the Nurses' Health Study II. <i>Breast Cancer Research</i> , 2012, 14, R44.	5.0	16
360	Insulin-like Growth Factor Pathway Genetic Polymorphisms, Circulating IGF1 and IGFBP3, and Prostate Cancer Survival. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	6.3	16

#	ARTICLE	IF	CITATIONS
361	Insulin-like growth factor-I induces CLU expression through Twist1 to promote prostate cancer growth. <i>Molecular and Cellular Endocrinology</i> , 2014, 384, 117-125.	3.2	16
362	High Sensitivity of an Ha-RAS Transgenic Model of Superficial Bladder Cancer to Metformin Is Associated with \sim 240-Fold Higher Drug Concentration in Urine than Serum. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 430-438.	4.1	16
363	Menstrual cycle characteristics and steroid hormone, prolactin, and growth factor levels in premenopausal women. <i>Cancer Causes and Control</i> , 2017, 28, 1441-1452.	1.8	16
364	Subclinical hypothyroidism and the risk of cancer incidence and cancer mortality: a systematic review. <i>BMC Endocrine Disorders</i> , 2020, 20, 83.	2.2	16
365	Repression of LKB1 by miR-17 \sim 492 Sensitizes MYC-Dependent Lymphoma to Biguanide Treatment. <i>Cell Reports Medicine</i> , 2020, 1, 100014.	6.5	16
366	Metabolic heterogeneity signature of primary treatment-naïve prostate cancer. <i>Oncotarget</i> , 2017, 8, 25928-25941.	1.8	16
367	Circulating insulin-like growth factors and risks of overall, aggressive and early-onset prostate cancer: a collaborative analysis of 20 prospective studies and Mendelian randomization analysis. <i>International Journal of Epidemiology</i> , 2023, 52, 71-86.	1.9	16
368	Enhancement of the Anti-Neoplastic Effects of Tamoxifen by Somatostatin Analogues. <i>Digestion</i> , 1996, 57, 29-33.	2.3	15
369	No Association between Serum Insulin-Like Growth Factor (IGF)-I, IGF-Binding Protein-3, and Lung Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 2010-2012.	2.5	15
370	Germ line knockout of IGFBP-3 reveals influences of the gene on mammary gland neoplasia. <i>Breast Cancer Research and Treatment</i> , 2015, 149, 577-585.	2.5	15
371	Incretin-based Drugs and the Incidence of Colorectal Cancer in Patients with Type 2 Diabetes. <i>Epidemiology</i> , 2018, 29, 246-253.	2.7	15
372	Other novel agents: Rationale and current status as chemopreventive agents. <i>Urology</i> , 2001, 57, 86-89.	1.0	14
373	Serum insulin-like growth factor (IGF) \sim 1 and IGF-binding protein \sim 3 do not correlate with Gleason score or quantity of prostate cancer in biopsy samples. <i>BJU International</i> , 2003, 92, 699-702.	2.5	14
374	IGF-I, IGFBP-3, and IGF-I/IGFBP-3 Ratio: No Association with Incident Colorectal Cancer in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 1832-1834.	2.5	14
375	Effect of Isocaloric Low Fat Diet on Prostate Cancer Xenograft Progression in a Hormone Deprivation Model. <i>Journal of Urology</i> , 2010, 183, 1619-1624.	0.4	14
376	A Prospective Study of Insulin-Like Growth Factor 1, Its Binding Protein 3, and Risk of Endometriosis. <i>American Journal of Epidemiology</i> , 2015, 182, 148-156.	3.4	14
377	Insulinlike Growth Factor Binding Protein-1 and Ghrelin Predict Health Outcomes Among Older Adults: Cardiovascular Health Study Cohort. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 267-278.	3.6	14
378	Interactions of the Insulin-Like Growth Factor Axis and Vitamin D in Prostate Cancer Risk in the Prostate Cancer Prevention Trial. <i>Nutrients</i> , 2017, 9, 378.	4.1	14

#	ARTICLE	IF	CITATIONS
379	The associations of anthropometric, behavioural and sociodemographic factors with circulating concentrations of IGF-1, IGF-II, IGFBP-1, IGFBP-2 and IGFBP-3 in a pooled analysis of 16,024 men from 22 studies. <i>International Journal of Cancer</i> , 2019, 145, 3244-3256.	5.1	14
380	Study protocol of a phase II clinical trial of oral metformin for the intravesical treatment of non-muscle invasive bladder cancer. <i>BMC Cancer</i> , 2019, 19, 1133.	2.6	14
381	Randomized Phase II Trial of Exercise, Metformin, or Both on Metabolic Biomarkers in Colorectal and Breast Cancer Survivors. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkz096.	2.9	14
382	The question of a link between insulin-like growth factor physiology and neoplasia. <i>Growth Hormone and IGF Research</i> , 2000, 10, S21-S24.	1.1	13
383	Competing risks of death in younger and older postmenopausal breast cancer patients. <i>World Journal of Clinical Oncology</i> , 2014, 5, 1088.	2.3	13
384	Glucagon-like peptide-1 analogues and risk of breast cancer in women with type 2 diabetes: population based cohort study using the UK Clinical Practice Research Datalink. <i>BMJ</i> , The, 2016, 355, i5340.	6.0	13
385	Simultaneous Extraction of RNA and Metabolites from Single Kidney Tissue Specimens for Combined Transcriptomic and Metabolomic Profiling. <i>Journal of Proteome Research</i> , 2018, 17, 3039-3049.	3.7	13
386	Effects of Adiposity and Exercise on Breast Tissue and Systemic Metabo-Inflammatory Factors in Women at High Risk or Diagnosed with Breast Cancer. <i>Cancer Prevention Research</i> , 2021, 14, 541-550.	1.5	13
387	Tissue-Specific Targeting of the Pthrp Gene: The Generation of Mice with Floxed Alleles. <i>Endocrinology</i> , 2001, 142, 2070-2077.	2.8	13
388	Regulation of IGFBP-3 expression in breast cancer cells and uterus by estradiol and antiestrogens: Correlations with effects on proliferation: A review. <i>Progress in Growth Factor Research</i> , 1995, 6, 495-501.	1.6	12
389	Intact and total insulin-like growth factor-binding protein-3 (IGFBP-3) levels in relation to breast cancer risk factors: a cross-sectional study. <i>Breast Cancer Research</i> , 2008, 10, R42.	5.0	12
390	Fasting insulin and endogenous hormones in relation to premenopausal breast density (Canada). <i>Cancer Causes and Control</i> , 2014, 25, 385-394.	1.8	12
391	Serum transforming growth factor- β 21 and risk of pancreatic cancer in three prospective cohort studies. <i>Cancer Causes and Control</i> , 2014, 25, 1083-1091.	1.8	12
392	Circulating resistin levels and risk of multiple myeloma in three prospective cohorts. <i>British Journal of Cancer</i> , 2017, 117, 1241-1245.	6.4	12
393	Mitomycin C and mitoxantrone chemotherapy for advanced breast cancer: efficacy with minimal gastrointestinal toxicity and alopecia. <i>Cancer Chemotherapy and Pharmacology</i> , 1990, 26, 457-460.	2.3	11
394	Metastatic Behavior of the RIF-1 Murine Fibrosarcoma: Inhibited by Hypophysectomy and Partially Restored by Growth Hormone Replacement. <i>Journal of the National Cancer Institute</i> , 1994, 86, 628-632.	6.3	11
395	Insulin-like growth factors and mammographic density. <i>Growth Hormone and IGF Research</i> , 2000, 10, S24-S25.	1.1	11
396	Serum C-peptide, Total and High Molecular Weight Adiponectin, and Pancreatic Cancer: Do Associations Differ by Smoking?. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 914-922.	2.5	11

#	ARTICLE	IF	CITATIONS
397	Insulin-like growth factor 1 receptor stabilizes the ETV6-NTRK3 chimeric oncoprotein by blocking its KPC1/Rnf123-mediated proteasomal degradation. <i>Journal of Biological Chemistry</i> , 2018, 293, 12502-12515.	3.4	11
398	Computer-aided information management systems in clinical trials. <i>Computer Programs in Biomedicine</i> , 1983, 16, 243-251.	0.7	10
399	In-vitro fertilisation and family history of breast cancer. <i>Lancet, The</i> , 1994, 344, 610-611.	13.7	10
400	Insulin-like growth factors and liver cancer risk in male smokers. <i>British Journal of Cancer</i> , 2010, 103, 1089-1092.	6.4	10
401	Binding between Insulin-like Growth Factor 1 and Insulin-like Growth Factor-binding Protein 3 Is Not Influenced by Glucose or 2-Deoxy-d-glucose. <i>Journal of Biological Chemistry</i> , 2011, 286, 16567-16573.	3.4	10
402	Stimulation of MC38 tumor growth by insulin analog X10 involves the serine synthesis pathway. <i>Endocrine-Related Cancer</i> , 2012, 19, 557-574.	3.1	10
403	Racial variation in umbilical cord blood sex steroid hormones and the insulin-like growth factor axis in African-American and white female neonates. <i>Cancer Causes and Control</i> , 2012, 23, 445-454.	1.8	10
404	Influence of Fasting Status and Sample Preparation on Metabolic Biomarker Measurements in Postmenopausal Women. <i>PLoS ONE</i> , 2016, 11, e0167832.	2.5	10
405	The Association Between IGF-I and IGFBP-3 and Incident Diabetes in an Older Population of Men and Women in the Cardiovascular Health Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 4541-4547.	3.6	10
406	Interplay between ShcA Signaling and PGC-1 β Triggers Targetable Metabolic Vulnerabilities in Breast Cancer. <i>Cancer Research</i> , 2018, 78, 4826-4838.	0.9	10
407	Relationship of circulating insulin-like growth factor-I and binding proteins with mammographic density among women undergoing image-guided diagnostic breast biopsy. <i>Breast Cancer Research</i> , 2019, 21, 81.	5.0	10
408	Trimetrexate in untreated and previously treated patients with metastatic breast cancer: A cancer and leukemia group b study. <i>Medical and Pediatric Oncology</i> , 1991, 19, 283-288.	1.0	9
409	First International Workshop on Growth Hormone, Insulin-like Growth Factors and Neoplasia. <i>Growth Hormone and IGF Research</i> , 2000, 10, S1-S3.	1.1	9
410	Metformin and Hepatic Carcinogenesis. <i>Cancer Prevention Research</i> , 2012, 5, 500-502.	1.5	9
411	Oncogenic kinases and perturbations in protein synthesis machinery and energetics in neoplasia. <i>Journal of Molecular Endocrinology</i> , 2019, 62, R83-R103.	2.5	9
412	Plasma Biomarkers of Insulin and the Insulin-like Growth Factor Axis, and Risk of Colorectal Adenoma and Serrated Polyp. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz056.	2.9	9
413	Intense exercise for survival among men with metastatic castrate-resistant prostate cancer (INTERVAL) Tj ETQq1 1 0.784314 rgBT /Over <i>Oncology</i> , 2016, 34, TPS5092-TPS5092.	1.6	9
414	Exercise Does Not Counteract the Effects of a "Westernized" Diet on Prostate Cancer Xenografts. <i>Prostate</i> , 2013, 73, 1223-1232.	2.3	8

#	ARTICLE	IF	CITATIONS
415	Associations between time spent sitting and cancer-related biomarkers in postmenopausal women: an exploration of effect modifiers. <i>Cancer Causes and Control</i> , 2014, 25, 1427-1437.	1.8	8
416	Serum insulin-like growth factor (IGF)-I and IGF binding protein-3 in relation to terminal duct lobular unit involution of the normal breast in Caucasian and African American women: The Susan G. Komen Tissue Bank. <i>International Journal of Cancer</i> , 2018, 143, 496-507.	5.1	8
417	Energy Metabolism, Cancer Risk, and Cancer Prevention. <i>Recent Results in Cancer Research</i> , 2009, 181, 51-54.	1.8	8
418	Serum markers, obesity and prostate cancer risk: results from the prostate cancer prevention trial. <i>Endocrine-Related Cancer</i> , 2022, 29, 99-109.	3.1	8
419	Vitamin D Pathway Polymorphisms in Relation to Mammographic Breast Density. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 2505-2508.	2.5	7
420	Prediagnosis Circulating Insulin-Like Growth Factors and Pancreatic Cancer Survival. <i>Annals of Surgical Oncology</i> , 2017, 24, 3212-3219.	1.5	7
421	Cancer Immunoprevention: A Case Report Raising the Possibility of "Immuno-interception". <i>Cancer Prevention Research</i> , 2020, 13, 351-356.	1.5	7
422	Macronutrient Intake and Cancer: How Does Dietary Restriction Influence Tumor Growth and Why Should We Care?. <i>Cancer Prevention Research</i> , 2009, 2, 698-701.	1.5	6
423	Similarity of Serum and Plasma Insulin-like Growth Factor Concentrations. <i>Biomarkers in Cancer</i> , 2015, 7, BIC.S23088.	3.6	6
424	Agreement between circulating IGF-I, IGFBP-1 and IGFBP-3 levels measured by current assays versus unavailable assays previously used in epidemiological studies. <i>Growth Hormone and IGF Research</i> , 2016, 26, 11-16.	1.1	6
425	A phenotype of IGFBP-3 knockout mice revealed by dextran sulfate-induced colitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 146-153.	2.8	6
426	Pilot Study Assessing Tolerability and Metabolic Effects of Metformin in Patients With Li-Fraumeni Syndrome. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa063.	2.9	6
427	IGF-Binding Proteins, Adiponectin, and Survival in Metastatic Colorectal Cancer: Results From CALGB (Alliance)/SWOG 80405. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkaa074.	2.9	6
428	Pre- and Postoperative Circulating IGF-I, IGFBP-3, and IGFBP-7 Levels in Relation to Endocrine Treatment and Breast Cancer Recurrence: A Nested Case-Control Study. <i>Frontiers in Oncology</i> , 2021, 11, 626058.	2.8	6
429	Dual effects of metformin on breast cancer proliferation in a randomized trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 519-519.	1.6	6
430	Enhancement of the Antineoplastic Effects of Tamoxifen by Somatostatin Analogues. , 1996, , 359-368.		6
431	Circulating Insulin-Like Growth Factor -Related Biomarkers and Risk of Lethal Prostate Cancer. <i>JNCI Cancer Spectrum</i> , 2022, 6, pkab091.	2.9	6
432	Diet boosts the effectiveness of a cancer drug. <i>Nature</i> , 2018, 560, 439-440.	27.8	5

#	ARTICLE	IF	CITATIONS
433	Effects of obesity on breast aromatase expression and systemic metabo-inflammation in women with BRCA1 or BRCA2 mutations. <i>Npj Breast Cancer</i> , 2021, 7, 18.	5.2	5
434	Blood biomarkers reflect the effects of obesity and inflammation on the human breast transcriptome. <i>Carcinogenesis</i> , 2021, 42, 1281-1292.	2.8	5
435	Combination chemotherapy with carboplatin and bleomycin for advanced and recurrent head and neck cancer: A phase II study. <i>Journal of Surgical Oncology</i> , 1988, 39, 215-216.	1.7	4
436	Potential role for somatostatin analogues in breast cancer: Rationale and description of an ongoing trial. <i>Metabolism: Clinical and Experimental</i> , 1992, 41, 119-120.	3.4	4
437	Androgen deprivation therapy and the risk of colorectal cancer in patients with prostate cancer. <i>Cancer Causes and Control</i> , 2013, 24, 839-845.	1.8	4
438	Octreotide LAR and tamoxifen versus tamoxifen in phase III randomize early breast cancer trials: NCIC CTG MA.14 and NSABP B-29. <i>Breast Cancer Research and Treatment</i> , 2015, 153, 353-360.	2.5	4
439	Association of Adiponectin and Vitamin D With Tumor Infiltrating Lymphocytes and Survival in Stage III Colon Cancer. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab070.	2.9	4
440	Clinicopathologic features of breast cancers diagnosed in women treated with prior radiation therapy for Hodgkin lymphoma: Results from a population-based cohort. <i>Cancer</i> , 2022, 128, 1365-1372.	4.1	4
441	A Mathematical Model Describing Consequences of Abnormally High Levels of Epidermal Growth Factor Receptor on the Proliferation of Neoplastic Cells. <i>Cancer Investigation</i> , 1991, 9, 513-520.	1.3	3
442	Insulin-like growth factor-I and risk of breast cancer. <i>Lancet, The</i> , 1998, 352, 489.	18.7	3
443	Variant NKX3.1 and Serum IGF-1: Investigation of Interaction in Prostate Cancer. <i>Genes and Cancer</i> , 2013, 4, 535-545.	1.9	3
444	Circulating IGF-axis protein levels and their relation with levels of plasma adipocytokines and macronutrient consumption in women. <i>Growth Hormone and IGF Research</i> , 2014, 24, 142-149.	1.1	3
445	Serum IGFBP-2 and Risk of Atypical Hyperplasia of the Breast. <i>Journal of Cancer Epidemiology</i> , 2015, 2015, 1-7.	1.1	3
446	Cancer, obesity, and diabetes: TKIs exert multiple effects on glucose homeostasis. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 268-268.	27.6	3
447	Prediagnostic use of low-dose aspirin and risk of incident metastasis and all-cause mortality among patients with colorectal cancer. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 2266-2273.	2.4	3
448	Expression of insulin-like growth factor receptor, IGF-1, and IGF-2 in primary and metastatic osteosarcoma. , 1998, 69, 21.		2
449	Abstract CT-04: A phase II study of neoadjuvant metformin in prostatic carcinoma. , 2012, , .		2
450	Metformin to treat prostate cancer (PCa) and prevent metabolic syndrome associated with androgen deprivation therapy (ADT): Results of a randomized double-blind placebo-controlled study of metformin in non-diabetic men initiating ADT for advanced PCa.. <i>Journal of Clinical Oncology</i> , 2017, 35, e16502-e16502.	1.6	2

#	ARTICLE	IF	CITATIONS
451	Metformin and biomarkers relevant to neoplasia in nondiabetic patients.. Journal of Clinical Oncology, 2013, 31, e14615-e14615.	1.6	2
452	Mitochondrial complex IV defects induce metabolic and signaling perturbations that expose potential vulnerabilities in HCT116 cells. FEBS Open Bio, 2022, 12, 959-982.	2.3	2
453	Re: Mutagen Sensitivity as a Risk Factor for Second Malignant Tumors Following Malignancies of the Upper Aerodigestive Tract. Journal of the National Cancer Institute, 1995, 87, 458-458.	6.3	1
454	The Human Mammary-Derived Growth Inhibitor (MDGI) Gene: Genomic Structure and Mutation Analysis in Human Breast Tumors. Genomics, 1996, 36, 377.	2.9	1
455	Overexpression of insulin-like growth factor binding protein 4 (IGFBP-4) in MCF-7 breast cancer cells is associated with reduced responsiveness to insulin-like growth factors in vitro and reduced tumour growth in vivo. International Journal of Oncology, 1997, 11, 193-7.	3.3	1
456	Cancer controversy. Nature, 1998, 392, 752-752.	27.8	1
457	I.4 Effects of anti-oestrogens on insulin-like growth factor (IGF-I) physiology systemically and in the uterus. European Journal of Cancer, 1998, 34, S11-S12.	2.8	1
458	Aging, IGF-1, and diet. Aging Cell, 2009, 8, 214-214.	6.7	1
459	Beyond steroid hormones: the new cancer endocrinology. Lancet Oncology, The, 2010, 11, 501-502.	10.7	1
460	Reply: "Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab". British Journal of Cancer, 2011, 105, 1467-1467.	6.4	1
461	Cancer Prevention. Cancer Prevention Research, 2019, 12, 1-2.	1.5	1
462	Prospective Association of Energy Balance Scores Based on Metabolic Biomarkers with Colorectal Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 974-981.	2.5	1
463	Association of plasma adiponectin with tumor infiltrating lymphocytes and survival in patients with stage III colon cancer (NCCTG N0147; Alliance).. Journal of Clinical Oncology, 2021, 39, 3591-3591.	1.6	1
464	Aspirin use in prostate cancer and the risk of death and metastasis.. Journal of Clinical Oncology, 2013, 31, 1518-1518.	1.6	1
465	Multicenter, randomized phase II trial of physical activity (PA), metformin (Met), or the combination on metabolic biomarkers in stage I-III colorectal (CRC) and breast cancer (BC) survivors.. Journal of Clinical Oncology, 2017, 35, 10059-10059.	1.6	1
466	Translational and HIF1-Dependent Metabolic Reprogramming Underpin Oncometabolome Plasticity and Synergy Between Oncogenic Kinase Inhibitors and Biguanides. SSRN Electronic Journal, 0, , .	0.4	1
467	IGF Signaling Is Critical for Growth and Survival of T-Cell Acute Lymphoblastic Leukemia Cells and Is Potentiated by Notch Upregulation of IGF1R. Blood, 2008, 112, 3811-3811.	1.4	1
468	Abstract 29: Design of a phase I chemoprevention study of metformin and Li-Fraumeni syndrome (LFS)., 2014, , .		1

#	ARTICLE	IF	CITATIONS
469	Translational Advances in Cancer Prevention Agent Development (TACPAD) Virtual Workshop on Immunomodulatory Agents: Report. <i>Journal of Cancer Prevention</i> , 2021, 26, 309-317.	2.0	1
470	Insulin-like Growth Factor Binding Protein-3 Induces Apoptosis in MCF7 Breast-Cancer Cells. <i>Biochemical and Biophysical Research Communications</i> , 1997, 240, 246.	2.1	0
471	Re: Italian Randomized Trial Among Women With Hysterectomy: Tamoxifen and Hormone-Dependent Breast Cancer in High-Risk Women. <i>Journal of the National Cancer Institute</i> , 2003, 95, 917-917.	6.3	0
472	Individualizing Interventions for Cancer Prevention. , 2005, 166, 63-70.		0
473	Correction: Adiponectin Inhibits Cancer Cell Proliferation. <i>Cancer Prevention Research</i> , 2009, 2, 95-95.	1.5	0
474	Reply to P. Ameri et al. <i>Journal of Clinical Oncology</i> , 2012, 30, 1396-1396.	1.6	0
475	The insulinâ€“insulin-like growth-factor receptor family as a therapeutic target in oncology. , 0, , 110-118.		0
476	Relapse-free survival of statistically standardized continuous RT-PCR estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2): NCIC CTG MA.14. <i>Breast Cancer Research and Treatment</i> , 2016, 157, 101-108.	2.5	0
477	Clinicopathologic features of breast cancers diagnosed in females treated with prior radiation therapy for Hodgkin lymphoma: Results from a population-based cohort.. <i>Journal of Clinical Oncology</i> , 2021, 39, 567-567.	1.6	0
478	Insights into the pharmacologic inhibition of insulin receptor tyrosine kinase in cancer: avoiding severe metabolic toxicity. <i>FASEB Journal</i> , 2010, 24, 1b442.	0.5	0
479	Metformin Abolishes Increased Tumor FDG Uptake Associated With a Highâ€“Energy Diet. <i>FASEB Journal</i> , 2011, 25, 1b314.	0.5	0
480	Low vs. high glycemic load diets reduce insulinâ€“like growth factors and inflammatory factors in overweight persons in a controlled feeding study. <i>FASEB Journal</i> , 2011, 25, 94.7.	0.5	0
481	Binding between IGFâ€“1 and IGFBPâ€“3 is not influenced by glucose or 2â€“DG. <i>FASEB Journal</i> , 2011, 25, 1b135.	0.5	0
482	High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by Notch signaling. <i>Journal of Cell Biology</i> , 2011, 194, i8-i8.	5.2	0
483	Randomized trials of adjuvant tamoxifen versus tamoxifen and octreotide LAR in early-stage breast cancer: NCIC CTG MA.14 and NSABP B-29.. <i>Journal of Clinical Oncology</i> , 2012, 30, 538-538.	1.6	0
484	Assessment of the prognostic and predictive utility of the breast cancer index (BCI): An NCIC CTG MA.14 study.. <i>Journal of Clinical Oncology</i> , 2012, 30, 561-561.	1.6	0
485	A phase II trial of neoadjuvant metformin in prostatic adenocarcinoma with serum and tissue biomarker evaluation.. <i>Journal of Clinical Oncology</i> , 2012, 30, e15118-e15118.	1.6	0
486	Individual insulin use and the risk of breast cancer: An international clinical epidemiology study.. <i>Journal of Clinical Oncology</i> , 2013, 31, 1578-1578.	1.6	0

#	ARTICLE	IF	CITATIONS
487	Final results of a phase II study of neoadjuvant metformin in prostatic carcinoma.. Journal of Clinical Oncology, 2013, 31, 5070-5070.	1.6	0
488	Pioglitazone and the risk of prostate cancer.. Journal of Clinical Oncology, 2016, 34, e16574-e16574.	1.6	0
489	Incidence of periprostatic white adipose tissue inflammation in men with prostate cancer.. Journal of Clinical Oncology, 2017, 35, 63-63.	1.6	0
490	A Hydride Transfer Complex Reprograms NAD Metabolism Preventing Senescence. SSRN Electronic Journal, 0, , .	0.4	0
491	Biomarkers of Glucose Homeostasis and Inflammation with Risk of Prostate Cancer: A Caseâ€“Cohort Study. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 736-743.	2.5	0